• Read more about Karen Gruber, RN, BSN, CEN, NE-BC

A member of nursing for 32 years, Ms. Gruber has also been instrumental in the growth of emergency medicine nursing at Cooper.

• Read more about Eileen F. Campbell, MSN, APN, FNP-BC

Ms. Campbell is the Chief Advanced Practice Provider. Her administrative responsibilities include oversight and standardization of recruitment/retention, professional development and engagement, quality and safety, education and research activities for Advanced Practice Providers (APPs) and Licensed Independent Practitioners (LIPs). This broad oversight includes Nurse Practitioners, Physician Assistants, CRNAs and Psychologists. Ms.

• Read more about Diane Floyd, BSN, MSN, CCRN, TCRN, NE-BC

Ms. Floyd started her nursing career in 1981 graduating with a diploma in nursing and immediately transitioned into critical care. Years at the bedside and desire to grow both in skill and knowledge resulted in further pursuit of career goals including a BSN and later a Master of Science in Nursing with an Emphasis in Nursing Education (MSN-Ed) degree.

• Read more about Kathy Devine, DrNP, RN, NEA-BC

Dr. Devine is responsible for professional nursing practice across the continuum of care to ensure safety, service, and quality outcomes for Cooper University Health Care's diverse patient population. In addition, she has administrative and operational leadership responsibility for Nursing and Patient Care Services. As SVP/CNE, Dr. Devine continues to advance nursing practice by engaging nurses in re-defining a professional practice model and shared governance structure that are grounded in theoretical tenets which align to organizational mission, vision, and values.

• Read more about M20-621

Short Title: M20-621

The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed.

Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, followed by epcoritamab or R-CHOP followed by rituximab will be explored.

In the Arm 1, participants will receive subcutaneous epcoritamab combined with intravenous and oral R-CHOP followed by subcutaneous epcoritamab in 21-day cycles. In the Arm 2, participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles.

Study Number:

M20-621

Study Status:

Enrolling

Treatment Agent:

Epcoritamab, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone

Resources and Links

National Clinical Trial Identified Number: NCT05578976

Disease:

• Diffuse Large B-Cell Lymphoma

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Anil K. Rengan, MD

Department:

• Hematology and Medical Oncology

• Read more about MDA 2023-0228 dMMR Phoenix

Short Title: Phoenix

To learn if cemiplimab can help to control dMMR colon cancer.

Study Number:

2023-0228

Study Status:

Enrolling

Treatment Agent:

Cemiplimab

Resources and Links

National Clinical Trial Identified Number: NCT05961709

Disease:

• Colon

Study Phase:

II

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Jamin C. Morrison, MD, MBA

Department:

• Hematology and Medical Oncology,
• Colon Cancer Stages

• Read more about MDA 2016-0046 Exceptional Responders

Short Title: Exceptional Responders

This clinical trial studies eliminating surgery and how well radiation therapy after systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided biopsy shows no residual cancer. Patients then receive standard breast radiotherapy.

Study Number:

2016-0046

Study Status:

Enrolling

Treatment Agent:

Radiation, Surgery

Resources and Links

National Clinical Trial Identified Number: NCT02945579

Disease:

• Breast Cancer,
• Estrogen Receptor Negative,
• HER2 Positive Breast Carcinoma,
• HER2/Neu Negative,
• Invasive Breast Carcinoma,
• Progesterone Receptor Negative,
• Triple-Negative Breast Carcinoma,
• Stage 1A, 1B, II, IIA, IIB

Study Phase:

Not applicable

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Catherine E. Loveland-Jones, MD, MS, FACS

• Read more about EVoPAR-Prostate 01

Short Title: EVoPAR - Prostate 01  

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Study Number:

AZD5305 - D9723C00001

Study Status:

Enrolling

Treatment Agent:

Saruparib, Abiraterone Acetate, Darolutamide, Enzalutamide

Resources and Links

National Clinical Trial Identified Number: NCT06120491

Disease:

• Metastatic Castration-Sensitive Prostate Cancer,
• Prostate Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Index Extra:

prostate

Hide from Search:

Off

Physician Name:

• Christian Squillante, MD

Department:

• Hematology and Medical Oncology

• Read more about CompassHER2

Short Title: CompassHER2

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.

Study Number:

A011801

Study Status:

Enrolling

Treatment Agent:

Trastuzumab emtansine, Tucatinib

Resources and Links

National Clinical Trial Identified Number: NCT04457596

Disease:

• HER2 Positive Breast Carcinoma,
• Invasive Breast Carcinoma,
• Multifocal Breast Carcinoma,
• Synchronous Bilateral Breast Carcinoma

Study Phase:

III

ResearchCancer@CooperHealth.edu

Hide from Search:

Off

Physician Name:

• Rebecca J. Jaslow, MD

Department:

• Breast Cancer

• Read more about DIRECT

Short Title: DIRECT

This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside the body. The use of FDG-PET/CT may help doctors better decide if a patient needs more or less treatment before surgery in order to get the best response. This study evaluates whether FDG-PET/CT is useful in predicting a patient's response to standard of care chemotherapy.

Study Number:

EA1211

Study Status:

Enrolling

Treatment Agent:

Chemotherapy

Resources and Links

National Clinical Trial Identified Number: NCT05710328

Disease:

• HER2-Positive Breast Carcinoma,
• Invasive Breast Carcinoma

Study Phase:

II

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Kamel Abou Hussein, MD

Department:

• Breast Cancer